Prior multiple ethanol withdrawals enhance stress-induced anxiety-like behavior: inhibition by CRF1- and benzodiazepine-receptor antagonists and a 5-HT1a-receptor agonist.
Repeated withdrawals from chronic ethanol induce a persistent adaptive change. Further, stress substitutes for the initial two withdrawals of a multiple-withdrawal protocol to sensitize rats to withdrawal-induced anxiety-like behavior ('anxiety'). Therefore, it was tested whether the persistent adaptation induced by multiple-withdrawal exposures allows stress to elicit anxiety after a period of abstinence. Social interaction was used to assess the degree of anxiety induced by 45 min of restraint stress 3, 7, or 14 days after rats were exposed to multiple withdrawals from a chronic 4.5% ethanol diet. Restraint stress reduced social interaction (ie anxiety-like behavior) at 3, but not at 7 or 14 days, after the multiple withdrawals. No anxiety response was observed in animals that received multiple withdrawals without stress or in animals that received stress when exposed only to control liquid diet. Drugs (ie a CRF1-receptor antagonist, a benzodiazepine receptor antagonist, and a 5-HT1A-receptor agonist) previously demonstrated to block the cumulative adaptation, when administered during repeated withdrawals, prevented stress-induced anxiety-like behavior during abstinence. Additionally, these drugs applied prior to stress in the rats previously exposed to the repeated withdrawal protocol, likewise, minimized stress-induced anxiety. The anxiety following stress during abstinence from previous chronic ethanol exposure is indicative of an interaction of stress with the persistent adaptive change caused by repeated withdrawals. Stress eliciting anxiety-like behavior during abstinence from previous ethanol exposures in rats is consistent with stress inducing anxiety during recovery (sobriety) in the alcoholic, a circumstance that can facilitate craving and relapse.
Breese
George R
GR
Bowles Center for Alcohol Studies, Department of Psychiatry, School of Medicine, University of North Carolina, Chapel Hill, NC 27599-7178, USA. george_breese@med.unc.edu
Overstreet
David H
DH
Knapp
Darin J
DJ
Navarro
Montserrat
M
D000704:Analysis of Variance; D000818:Animals; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000209:etiology; D001522:Behavior, Animal / Q000187:drug effects; D002065:Buspirone / Q000008:administration & dosage; D002492:Central Nervous System Depressants / Q000008:administration & dosage*; D004347:Drug Interactions; D000431:Ethanol / Q000009:adverse effects*; D005442:Flumazenil / Q000008:administration & dosage; D005526:Food, Formulated; D018757:GABA Modulators / Q000008:administration & dosage; D007398:Interpersonal Relations; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D012149:Restraint, Physical / Q000379:methods; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D013315:Stress, Psychological / Q000150:complications; D013375:Substance Withdrawal Syndrome / Q000209:etiology / Q000503:physiopathology*; D013997:Time Factors
D014151:Anti-Anxiety Agents; C101628:CP 154526; D002492:Central Nervous System Depressants; D018757:GABA Modulators; D011743:Pyrimidines; D011758:Pyrroles; D018019:Receptors, Corticotropin-Releasing Hormone; D017366:Serotonin Receptor Agonists; D000431:Ethanol; D005442:Flumazenil; D002065:Buspirone
Alcohol Alcohol. 1999 Mar-Apr;34(2):223-30
10344782
Psychopharmacology (Berl). 1998 Jan;135(2):169-74
9497022
Psychopharmacology (Berl). 2005 Apr;178(4):367-80
15765253
Alcohol Clin Exp Res. 2005 Apr;29(4):553-63
15834220
Alcohol Clin Exp Res. 2000 May;24(5):666-74
10832908
J Neural Transm (Vienna). 2000;107(6):613-38
10943904
J Neural Transm (Vienna). 2000;107(6):649-68
10943906
Psychopharmacology (Berl). 2001 Jan;153(3):315-20
11271403
Alcohol. 2000 Nov;22(3):159-64
11163123
Alcohol Clin Exp Res. 2001 Jul;25(7):999-1005
11505024
Psychopharmacology (Berl). 2001 Dec;158(4):343-59
11797055
Alcohol Clin Exp Res. 2002 Jun;26(6):785-95
12068246
Pharmacol Ther. 2002 Apr-May;94(1-2):137-56
12191599
Alcohol Clin Exp Res. 2002 Aug;26(8):1259-68
12198403
Alcohol Clin Exp Res. 2002 Oct;26(10):1494-501
12394282
Alcohol Alcohol. 2002 Nov-Dec;37(6):609-12
12414556
Eur J Pharmacol. 2003 Feb 28;463(1-3):35-53
12600701
Psychopharmacology (Berl). 2003 Jun;167(4):344-52
12677355
Alcohol. 2003 Feb;29(2):55-60
12782246
Alcohol Alcohol. 2003 Jul-Aug;38(4):360-3
12814905
Psychopharmacology (Berl). 2003 Jul;168(1-2):184-91
12447607
Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S255-8
14677088
Pharmacol Biochem Behav. 2004 Feb;77(2):405-13
14751471
Neuropsychopharmacology. 2004 Mar;29(3):470-82
12955093
Alcohol. 2004 Feb;32(2):101-11
15163561
Br J Pharmacol. 1978 Jan;62(1):19-24
563752
Drug Alcohol Depend. 1979 May-Jul;4(3-4):353-7
118857
J Neurosci Methods. 1980 Jun;2(3):219-38
6120260
J Pharmacol Exp Ther. 1983 Sep;226(3):720-5
6310080
Alcohol. 1985 May-Jun;2(3):501-5
4026971
Neuropsychobiology. 1985;13(4):194-200
2864655
J Abnorm Psychol. 1990 Nov;99(4):344-8
2266207
Alcohol Clin Exp Res. 1991 Jun;15(3):438-59
1898494
Brain Res. 1993 Mar 5;605(1):25-32
8467387
J Stud Alcohol. 1995 Sep;56(5):538-45
7475034
J Abnorm Psychol. 1997 May;106(2):243-50
9131844
Alcohol Clin Exp Res. 2005 Feb;29(2):185-95
15714042